Clinical Characteristics of COVID-19 Patients in a Regional Population with Diabetes Mellitus: The ACCREDIT Study

Abstract

Objective: To identify clinical and biochemical characteristics associated with 7-& 30day mortality and intensive care admission amongst diabetes patients admitted with COVID-19.Research Design and Methods: We conducted a cohort study collecting data from medical notes of hospitalised people with diabetes and COVID-19 in 7 hospitals within the Mersey-Cheshire region from 1 January to 30 June 2020. We also explored the impact on inpatient diabetes team resources. Univariate and multivariate logistic regression analyses were performed and optimised by splitting the dataset into a training, test, and validation sets, developing a robust predictive model for the primary outcome. Results:We analyzed data from 1004 diabetes patients (mean age 74.1 (± 12.6) years, predominantly men 60.7%). 45% belonged to the most deprived population quintile in the UK. Median BMI was 27.6 (IQR 23.9-32.4) kg/m 2 . The primary outcome (7-day mortality) occurred in 24%, increasing to 33% by day 30. Approximately one in ten patients required insulin infusion (9.8%). In univariate analyses, patients with type 2 diabetes had a higher risk of 7-day mortality [p < 0.05, OR 2.52 (1.06, 5.98)]. Patients requiring insulin infusion had a lower risk of death [p = 0.02, OR 0.5 (0.28, 0.9)]. CKD in younger patients

Random Blood Glucose, but Not HbA1c, Was Associated with Mortality in COVID-19 Patients with Type 2 Diabetes Mellitus—A Retrospective Study

“…Despite the aforementioned literature in support of the findings of this present study, those who reported otherwise are worth noting. A study of 1004 diabetic patients with COVID-19 found that HbA1c or RBG was statistically associated with mortality [ 30 ]. Another study involving 3,295 COVID-19 patients found that HbA1c was associated with severe COVID-19, ICU admission, or all-cause mortality in both diabetic and non-diabetic groups [ 31 ].…”